Physician profile
Ivan Chinn
NPI 1962670232
$11,010.54
in general payments reported to CMS, 2019-2025
8 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Pediatric Rheumatology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $75.00 · 2021: $500 · 2022: $617 · 2023: $9,328 · 2024: $327 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,338 · Travel and Lodging: $1,363 · Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,337.50 |
| Travel and Lodging | $1,362.60 |
| Food and Beverage | $1,118.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $6,578.49 | 2023 | Rethymic |
| Pharming Healthcare, INC. | $3,842.78 | 2021-2025 | Joenja, Ruconest |
| Grifols USA, LLC | $176.77 | 2023-2025 | Xembify |
| Grifols Shared Services North America, INC. | $122.55 | 2024 | Gamunex-C |
| Amgen INC. | $98.25 | 2024-2025 | Actimmune |
| Horizon Therapeutics Plc | $86.70 | 2022 | |
| Prugen, INC. Pharmaceuticals | $75.00 | 2020 | |
| Epi Health, LLC | $30.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Chinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.